| Cat. No. 250-11P |
100 µg peptide, lyophilized. For reconstitution add 100 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use. Control peptides should be stored at -20°C when still lyophilized! |
| Applications |
|
| Immunogen | Synthetic peptide corresponding to AA 522 to 541 from rat EAAT1 (UniProt Id: P24942) |
| Recommended dilution | Optimal concentrations should be determined by the end-user. |
| Matching antibodies | 250 113, 250 114, 250 116 |
| Remarks |
This control peptide consists of the synthetic peptide (aa 522 - 541 of rodent EAAT 1) that has been used for immunization. It has been tested in preadsorption experiments and blocks efficiently and specifically the corresponding signal in Western blots. The amount of peptide needed for efficient blocking depends on the titer and on the affinity of the antibody to the antigen. |
| Data sheet | 250-11p.pdf |
Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system. After the release of glutamate from synaptic vesicles into the synaptic cleft during neurotransmission, excitatory amino acid transporters (EAATs) remove extracellular glutamate to avoid excitotoxic levels (1).
Five EAATs with differential expression patterns have been described so far: EAAT1, also referred to as GLAST and SLC1A3, has neuroprotective potential following ischemia and occurs in reactive astrocytes and activated microglia. EAAT2 (GLT-1, SLC1A2) is the most abundant isoform and is primarily expressed in astrocytes. Both variants show high levels in brain and retina. EAAT3 / SLC1A1, EAAT4 / SLC1A6 and EAAT5 / SLC1A7 are expressed in neurons (2). EAAT4 shows weak expression in the forebrain and high levels in the cerebellum (3). EAAT5 primarily occurs in the retina where it locates very close to glutamate release sites. In K.O. mice flicker resolution is considerably compromised (4). Recent findings suggest that EAAT5 is an abundant isoform, expressed also in non-neuronal peripheral tissues (5).